183 related articles for article (PubMed ID: 19705496)
1. Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma.
Milosevic R; Todorovic M; Balint B; Jevtic M; Krstic M; Ristanovic E; Antonijevic N; Pavlovic M; Perunicic M; Petrovic M; Mihaljevic B
World J Gastroenterol; 2009 Aug; 15(32):4009-15. PubMed ID: 19705496
[TBL] [Abstract][Full Text] [Related]
2. Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma.
Wu Z; Zhou J; Wang X; Li YB; Niu T; Peng B
World J Gastroenterol; 2013 Jun; 19(24):3854-60. PubMed ID: 23840125
[TBL] [Abstract][Full Text] [Related]
3. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
4. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Kontopidou FN; Yiakoumis X; Kokoris SI; Dimitriadou EM; Dimopoulou MN; Moschogiannis M; Korkolopoulou P; Kyrtsonis MC; Siakantaris MP; Papadaki T; Tsaftaridis P; Plata E; Papadaki HE; Vassilakopoulos TP
Oncologist; 2013; 18(2):190-7. PubMed ID: 23345547
[TBL] [Abstract][Full Text] [Related]
5. Still a role for surgery as first-line therapy of splenic marginal zone lymphoma? Results of a prospective observational study.
Pata G; Bartoli M; Damiani E; Solari S; Anastasia A; Pagani C; Tucci A
Int J Surg; 2017 May; 41():143-149. PubMed ID: 28366762
[TBL] [Abstract][Full Text] [Related]
6. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Thieblemont C; Felman P; Berger F; Dumontet C; Arnaud P; Hequet O; Arcache J; Callet-Bauchu E; Salles G; Coiffier B
Clin Lymphoma; 2002 Jun; 3(1):41-7. PubMed ID: 12141954
[TBL] [Abstract][Full Text] [Related]
7. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic study of splenic marginal zone B-cell lymphoma].
Zhang YN; Zheng YY; Zhou XG; Zhang SH; Jin Y; Xie JL; Chen SY; Shi Y; Wu LH
Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):243-7. PubMed ID: 19575895
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.
Lenglet J; Traullé C; Mounier N; Benet C; Munoz-Bongrand N; Amorin S; Noguera ME; Traverse-Glehen A; Ffrench M; Baseggio L; Felman P; Callet-Bauchu E; Brice P; Berger F; Salles G; Brière J; Coiffier B; Thieblemont C
Leuk Lymphoma; 2014 Aug; 55(8):1854-60. PubMed ID: 24206091
[TBL] [Abstract][Full Text] [Related]
10. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base.
Fallah J; Olszewski AJ
Hematology; 2019 Dec; 24(1):378-386. PubMed ID: 30885066
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of splenic tumours of lymphoid tissue.
Chen DB; Shen DH; Yang SM; Fang XZ
Pathol Res Pract; 2018 Dec; 214(12):1952-1958. PubMed ID: 30087035
[TBL] [Abstract][Full Text] [Related]
13. [Progress on Treatment of Splenic Marginal Zone Lymphoma-Review].
Wu L; Tian C; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
[TBL] [Abstract][Full Text] [Related]
14. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
15. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
Kalpadakis C; Pangalis GA; Vassilakopoulos TP; Sachanas S; Angelopoulou MK
Leuk Lymphoma; 2014 Jul; 55(7):1463-70. PubMed ID: 24050506
[TBL] [Abstract][Full Text] [Related]
16. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
17. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
18. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma.
Olszewski AJ
Am J Hematol; 2012 Nov; 87(11):E119-22. PubMed ID: 22887176
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
